Journée de la Fédération d'Hématologie

5TH EDITION

Wednesday **8H30 - 17H**

18th November 2026

Maison des Associations et de Solidarité - Salle Emile Laffon
10-18 rue des terres du curé, 75013 Paris

8H30 *Welcome coffee*

9H – 10H30 Fondamental Research Session

Moderation: Christel Guillouf and Marie-Laure Arcangeli

Long Talks (10 min + 3 min Q/A)

Modeling chronic myelomonocytic leukemia to study the functional consequences of NRAS mutations.
Sébastian Nakhla, U1287 – Gustave Roussy

TEs as enhancers in inducing a myeloid bias upon TET2 loss.
Cheng Xuan , U1287 – Gustave Roussy

The role of RUNX1 in leukemia development mediated by the ETO2/GLIS2 fusion protein in pediatric AML.
Alexia Le Bourgeois, U1360 – Gustave Roussy

Investigating human lymphoid progenitor–mediated thymic regeneration to improve T-cell reconstitution after transplantation in aged patients.
Jeanne Roche-Naude, U1274 – CEA

TREM2+ macrophages drive CAR-T cell dysfunction and resistance in diffuse large B-cell lymphoma.
Camille Bigenwald – U1386, Gustave Roussy

Short Talks (4 min)

Characterization of a germinal variant of CUX1 in normal and pathological hematopoiesis.
Laëtitia Vuillemin, U1287 – Gustave Roussy

Modeling Ph-like leukemia to understand a new therapeutic approach.
Alix Izac Imbert, U1274 – CEA

Role of T lymphocytes and their interactions with megakaryocytes in the development of myelofibrosis.
Merwan Saddar, U1287 – Gustave Roussy

10H30 - 11H *Coffee Break*

11H – 12H Clinical and Translational Hematology Session

Moderation: Juliette Lambert and Camille Bigenwald

Long Talks (10 min + 3 min Q/A)

Recommendations and research projects on Burkitt Lymphoma.
Caroline Besson – UVSQ, Université Paris-Saclay, Inserm U550, CESP, Villejuif

A collaborative network bringing together clinical, biological and scientific expertise to advance myeloproliferative neoplasm research and care.
Laurence Legros – APHP - Univ. Paris Saclay - Hôpital Bicêtre

Therapy-related versus de novo myeloid neoplasms in the NGS era: clinical, molecular and prognostic heterogeneity in a contemporary Gustave Roussy cohort.
Mohamad Ali Hachem – Gustave Roussy

Short Talks (4 min)

Long-read sequencing identifies novel fusion partners in AML and enables longitudinal MRD monitoring with patient-specific qPCR.
Thomas Steimle – Gustave Roussy

Hypoalbuminemia independently predicts survival in AML patients treated with azacitidine and venetoclax.
Christophe Willekens, U1287 – Gustave Roussy

Investigating BRAF V600E clone persistence during MAPK inhibition: experimental models, pathogenesis and therapeutic perspectives.
Florian Houdu, U1367 – Gustave Roussy

12H - 13H45 *Lunch*

13H45 - 14H **Annual report - Fédération d'hématologie**
The executive committee members

14H - 15H Keynote lecture

Moderation: Caroline Marty and Julien Calvo

The tumor microenvironment in follicular lymphomas: from description to clinical application.
Karin Tarte, CHU Rennes (50 min + 10 min Q/A)

15H - 15H30 *Coffee break*

15H30 - 16H30 Technology Highlights

Moderation: Laure Delestre and Stéphanie Gachet

Deep learning and computational methods for spatial data analysis.
Quentin Blampey, Gustave Roussy (20 min + 10 min Q/A)

RNA Vectorization: a critical challenge for new therapeutic applications.
François Fay, Univ. Paris Saclay (20 min + 10 min Q/A)

16H30 - 16H45 *End of the day*

WITH THE SUPPORT OF GSK SERVIER abbvie

WWW.FEDERATION-HEMATOLOGY-UPSACLAY.COM